- Home
- GNLX vs CRBU Comparison
GNLX vs CRBU Comparison
Compare GNLX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- CRBU
- Stock Information
- Founded
- GNLX 2001
- CRBU 2011
- Country
- GNLX United States
- CRBU United States
- Employees
- GNLX N/A
- CRBU N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- GNLX Health Care
- CRBU Health Care
- Exchange
- GNLX Nasdaq
- CRBU Nasdaq
- Market Cap
- GNLX 112.8M
- CRBU 93.0M
- IPO Year
- GNLX 2023
- CRBU 2021
- Fundamental
- Price
- GNLX $3.09
- CRBU $1.38
- Analyst Decision
- GNLX Strong Buy
- CRBU Strong Buy
- Analyst Count
- GNLX 4
- CRBU 4
- Target Price
- GNLX $17.75
- CRBU $8.50
- AVG Volume (30 Days)
- GNLX 137.5K
- CRBU 1.8M
- Earning Date
- GNLX 08-13-2025
- CRBU 08-05-2025
- Dividend Yield
- GNLX N/A
- CRBU N/A
- EPS Growth
- GNLX N/A
- CRBU N/A
- EPS
- GNLX N/A
- CRBU N/A
- Revenue
- GNLX N/A
- CRBU $9,918,000.00
- Revenue This Year
- GNLX N/A
- CRBU $12.83
- Revenue Next Year
- GNLX N/A
- CRBU N/A
- P/E Ratio
- GNLX N/A
- CRBU N/A
- Revenue Growth
- GNLX N/A
- CRBU N/A
- 52 Week Low
- GNLX $1.60
- CRBU $0.66
- 52 Week High
- GNLX $5.89
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- GNLX 56.10
- CRBU 61.54
- Support Level
- GNLX $2.75
- CRBU $1.22
- Resistance Level
- GNLX $3.17
- CRBU $1.44
- Average True Range (ATR)
- GNLX 0.24
- CRBU 0.11
- MACD
- GNLX -0.00
- CRBU -0.00
- Stochastic Oscillator
- GNLX 56.94
- CRBU 82.50
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.